Soluble semicarbazide-sensitive amine oxidase (SSAO) activity is related to oxidative stress and subchronic inflammation in streptozotocin-induced diabetic rats

Neurochemistry International

Volumn 48, Issue 8, 2006, Pages 746-752

  Somfai, Gábor Márk ^a   Knippel, Barbara ^a   Ruzicska, Éva ^a   Stadler, Krisztián ^b   Tóth, Miklós ^a,c   Salacz, György ^a   Magyar, Kálmán ^a,d   Somogyi, Anikó ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b CHEMICAL RESEARCH CENTER   (Hungary)

^c NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^d INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Alzheimer's disease; C reactive protein; Diabetes mellitus; Oxidative stress; Rat; Semicarbazide sensitive amine oxidase (SSAO); Streptozotocin

Indexed keywords

AMINE; AMINE OXIDASE (COPPER CONTAINING); C REACTIVE PROTEIN; CELL ADHESION MOLECULE; FRUCTOSE; INSULIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; INFLAMMATION; MALE; MULTIINFARCT DEMENTIA; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RISK FACTOR; SERUM; STATISTICAL SIGNIFICANCE; STREPTOZOCIN DIABETES;

ALZHEIMER DISEASE; AMINE OXIDASE (COPPER-CONTAINING); ANIMALS; ANTIOXIDANTS; BRAIN; C-REACTIVE PROTEIN; CEREBRAL ARTERIES; CEREBROVASCULAR DISORDERS; CHRONIC DISEASE; DEMENTIA, VASCULAR; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; ENCEPHALITIS; ENDOTHELIAL CELLS; ENZYME ACTIVATION; FRUCTOSE; MALE; OXIDATIVE STRESS; RATS; RATS, WISTAR; SOLUBILITY; UP-REGULATION;

ANIMALIA;

EID: 33646118236     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2005.12.009     Document Type: Article

References (44)

1. Abella A., Marti L., Camps M., Claret M., Alvarez J.F., Gomis R., Gumá A., Viguerie N., Carpéné C., Palacín M., Testar X., and Zorzano A. Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 activity exerts antidiabetic action in Goto-Kakizaki rats. Diabetes 52 (2003) 1004-1013
2. Abella A., Garcia-Vicente S., Viguerie N., Ros-Baró A., Camps M., Palacin M., Zorzano A., and Marti L. Adipocytes release a soluble form of VAP-1/SSAO by a metalloprotease-dependent process and in a regulated manner. Diabetologia 47 (2004) 429-438
3. Boomsma F., Derkx F.H., van den Meracker A.H., Man in 't Veld A.J., and Schalekamp M.A. Plasma semicarbazide-sensitive amine oxidase activity is elevated in diabetes mellitus and correlates with glycosylated hemoglobin. Clin. Sci. 88 (1995) 675-679
4. Boomsma F., van Dijk J., Bhaggoe U.M., Bouhuizen A.M., and van den Meiracker A.H. Variation in semicarbazide-sensitive amine oxidase activity in plasma and tissues of mammals. Comp. Biochem. Physiol. - Part C: Toxicology Pharmacol. 126 (2000) 69-78
5. Boor P.J., Trent M.B., Lyles G.A., Tao M., and Ansari G.A. Methylamine metabolism to formaldehyde by vascular semicarbazide-sensitive amine oxidase. Toxicology 73 (1992) 251-258
6. Callingham B.A., Crosbie A.E., and Rous B.A. Some aspects of the pathophysiology of semicarbazide-sensitive amine oxidase enzymes. Prog. Brain Res. 106 (1995) 305-321
7. Ceriello A., Quagliaro L., Piconi L., Assaloni R., Da Ros R., Maier A., Esposito K., and Giugliano D. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes 53 3 (2004) 701-710
8. Deng Y., and Yu P.H. Simultaneous determination of formaldehyde and methylglyoxal in urine: involvement of semicarbazide-sensitive amine oxidase-mediated deamination in diabetic complications. J. Chromatogr. Sci. 37 (1999) 317-322
9. del Mar Hernandez M., Esteban M., Szabo P., and Unzeta M. Human plasma semicarbazide sensitive amine oxidase (SSAO), beta-amyloid protein and aging. Neurosci. Lett. 384 (2005) 183-187
10. Ekblom J. Potential therapeutic value of drugs inhibiting semicarbazide-sensitive amine oxidase: vascular cytoprotection in diabetes mellitus. Pharmacol. Res. 37 (1998) 87-92
11. Ferrer I., Lizcano J.M., Hernandez M., and Unzeta M. Overexpression of semicarbazide sensitive amine oxidase in the cerebral blood vessels in patients with Alzheimer's disease and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Neurosci. Lett. 321 (2002) 21-24
12. Garpenstrand H., Ekblom J., Bäcklund L.B., Oreland L., and Rosenquist U. Elevated plasma semicarbazide-sensitive amine oxidase (SSAO) activity in Type 2 diabetes mellitus complicated by retinopathy. Diab. Med. 16 (1999) 514-521
13. Grimble R.F. Inflammatory status and insulin resistance. Curr. Opin. Clin. Nutr. Metab. Care 5 (2002) 551-559
14. Grönvall-Nordquist J.L., Backlund L.B., Garpenstrand H., Ekblom J., Landin B., Yu P.H., Oreland L., and Rosenqvist U. Follow-up of plasma semicarbazide-sensitive amine oxidase activity and retinopathy in Type 2 diabetes mellitus. J. Diab. Complications 15 5 (2001) 250-256
15. Jalkanen S., and Salmi M. Cell surface monoamine oxidases: enzymes in search of a function. EMBO J. 15 (2001) 3893-3901
16. Karádi I., Mészáros Z., Csányi A., Szombathy T., Hosszúfalusi N., Romics L., and Magyar K. Serum semicarbazide-sensitive amine oxidase (SSAO) activity is an independent marker of carotid atherosclerosis. Clin. Chim. Acta 323 (2002) 139-146
17. Kurkijärvi R., Yegutkin G.G., Gunson B.K., Jalkanen S., Salmi M., and Adams D.H. Circulating soluble vascular adhesion protein-1 accounts for the increased monoamine oxidase activity in chronic liver disease. Gastroenterology 119 (2000) 1096-1103
18. Libby P., and Ridker P.M. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am. J. Med. 116 Suppl. 6A (2004) 9S-16S
19. Lowry O.H., Rosenbrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
20. Lyles G.A., and Chalmers J. The metabolism of aminoacetone to methylglyoxal by semicarbazide-sensitive amine oxidase in human umbilical artery. Biochem. Pharmacol. 43 (1992) 1409-1414
21. Lyles G.A. Mammalian plasma and tissue-bound semicarbazide-sensitive amine oxidases: biochemical, pharmacological and toxicological aspects. Int. J. Biochem. Cell Biol. 28 (1996) 259-274
22. Magyar K., Meszaros Z., and Matyus P. Semicarbazide-sensitive amine oxidase. Its physiological significance. Pure Appl. Chem. 73 9 (2001) 1393-1400
23. Mátyus P., Dajka-Halász B., Földi A., Haider N., Barlocco D., and Magyar K. Semicarbazide-sensitive amine oxidase: current status and perspectives. Curr. Med. Chem. 11 (2004) 1285-1298
24. Meszaros Z., Karadi I., Csanyi A., Szombathy T., Romics L., and Magyar K. Determination of human serum semicarbazide-sensitive amine oxidase activity: a possible marker of atherosclerosis. Eur. J. Drug Metab. Pharmacokinet. 24 4 (1999) 299-302
25. Meszaros Z., Csanyi A., Vallus G., Szombathy T., Karadi I., and Magyar K. Inhibitor sensitivity of human serum and vascular semicarbazide-sensitive amine oxidases. Neurobiology (Bp) 8 2 (2000) 215-223
26. Mohanty P., Hamouda W., Garg R., Aljada A., Ghanim H., and Dandona P. Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J. Clin. Endocrinol. Metab. 85 8 (2000) 2970-2973
27. Pasceri V., Willerson J.T., and Yeh E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102 18 (2000) 2165-2168
28. Pradhan A.D., and Ridker P.M. Do atherosclerosis and type 2 diabetes share a common inflammatory basis?. Eur. Heart J. 23 (2002) 831-834
29. Praticó D., Uryu K., Leight S., Trojanowski J.Q., and Lee V.M.-Y. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J. Neurosci. 21 (2001) 4183-4187
30. Praticó D. Alzheimer's disease and oxygen radicals: new insights. Biochem. Pharmacol. 63 (2002) 563-567
31. Roberts W.L., Moulton L., Law T.C., Farrow G., Cooper-Anderson M., Savory J., and Rifai N. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clin. Chem. 47 (2001) 418-425
32. Salmi M., and Jalkanen S. A 90-kDa endothelial cell molecule mediating lymphocyte binding in humans. Science 257 (1992) 1407-1409
33. Salmi M., Yegutkin G.G., Lehvonen R., Koskinen K., Salminen T., and Jalkanen S. A cell surface amine oxidase directly controls lymphocyte migration. Immunity 14 3 (2001) 265-276
34. Stehouwer C.D., Gall M.A., Twisk J.W., Knudsen E., Emeis J.J., and Parving H.H. Increased urinary albumin excretion, endothelial dysfunction, and chronic lowgrade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 51 (2002) 1157-1165
35. Stewart W.F., Kawas C., Corrada M., and Metter E.J. Risk of Alzheimer's disease and duration of NSAID use. Neurology 48 (1997) 626-632
36. Stitt A.W., Li Y.M., Gardiner T.A., Bucala R., Archer D.B., and Vlassara H. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am. J. Pathol. 150 2 (1997) 523-531
37. Tan K.C., Chow W.S., Tam S.C., Ai V.H., Lam C.H., and Lam K.S. Atorvastatin lowers C-reactive protein and improves endothelium dependent vasodilation in type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 87 (2002) 563-568
38. Tan K.C., Chow W.S., Tam S., Bucala R., and Betteridge J. Association Between Acute-Phase Reactants and Advanced Glycation End Products in Type 2 Diabetes. Diab. Care 27 (2004) 223-228
39. Vlassara H., Brownlee M., Manogue K.R., Dinarello C.A., and Pasagian A. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 240 (1998) 1546-1548
40. Xu W.L., Qiu C.X., Wahlin A., Winblad B., and Fratiglioni L. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology 63 (2004) 1181-1186
41. Yu P.H., and Zuo D.M. Inhibition of a type B monoamine oxidase inhibitor, (E)-2-(4-fluorophenethyl)-3-fluoroallylamine (MDL-72974A), on semicarbazide-sensitive amine oxidases isolated from vascular tissues and sera of different species. Biochem. Pharmacol. 43 (1992) 307-312
42. Yu P.H., and Zuo D.M. Oxidative deamination of methylamine by semicarbazide-sensitive amine oxidase leads to cytotoxic damage in endothelial cells. Possible consequences for diabetes. Diabetes 42 (1993) 594-603
43. Yu P.H., and Zuo D.M. Aminoguanidine inhibits semicarbazide-sensitive amine oxidase activity: implications for advanced glycation and diabetic complications. Diabetologia 40 (1997) 1243-1250
44. Yu P.H. Involvement of cerebrovascular semicarbazide-sensitive amine oxidase in the pathogenesis of Alzheimer's disease and vascular dementia. Med. Hypotheses 57 (2001) 175-179